Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,467.60
(
0.25%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.51
(
-2.06%
)
Bitcoin
73,216.08
(
1.99%
)
News Focus
News Focus
Post# of 257376
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 04/13/2022 4:59:53 AM

Wednesday, April 13, 2022 4:59:53 AM

Post# of 257376
GSK acquires SRRA for $55/sh cash—a 39% premium to yesterday's close:

https://www.businesswire.com/news/home/20220411006012/en/

The nominal deal value is $1.9B.

SRRA's lead asset is Momelotinib, a JAK inhibitor that has passed through many companies (Cytopia, YM Biosciences, GILD, SRRA, and now GSK).

Note: SRRA implented a 1:40 reverse split in Jan 2020.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today